Opioid Substitution Therapy Halves Post-Release Death Risk for Prisoners, Government Data Shows

The Deadly Window After Prison Gates (Image Credits: Unsplash)

Reentering society after prison often means navigating a landscape fraught with relapse and overdose. A report released this week by UK government bodies examined thousands of such transitions and pinpointed a critical buffer: opioid substitution therapy, or OST, delivered right before release. The analysis, drawing on linked national datasets, demonstrated that prisoners receiving OST on their last day in custody faced half the mortality risk in the following four weeks compared to those who did not.[1][2]

The Deadly Window After Prison Gates

Prison release marks one of the most hazardous periods for individuals with substance use histories. Researchers tracked outcomes for 270,113 prison spells involving 155,235 people released from English prisons between August 2018 and December 2022. Within four weeks, 293 deaths occurred, equating to a 0.11 percent mortality rate overall.[1]

Almost half of these fatalities – 48.5 percent – struck in the first seven days. Drug-related causes dominated, accounting for 62.1 percent of all deaths in the period and 71.1 percent in that initial week. Those treated for opiates in prison showed the highest vulnerability at 0.21 percent, underscoring the urgency of interventions tailored to opioid users.[1]

This pattern aligns with longstanding evidence that lowered tolerance during incarceration heightens overdose susceptibility upon release. The report’s granular breakdown revealed drug-related deaths tapering over time: 101 in days zero to seven, dropping to 19 by days 22 to 28.[1]

Unveiling Patterns Through Data Linkage

The study’s power stemmed from merging three major datasets: the Ministry of Justice’s Prison National Offender Management Information System (p-NOMIS), the Office for National Statistics mortality register, and the National Drug Treatment Management System (NDTMS). This Better Outcomes Through Linked Data (BOLD) effort at the Department of Health and Social Care enabled precise tracking of treatment, deaths, and re-incarceration.[1][2]

Nearly 40 percent of spells – 39.6 percent – linked to prison-based substance misuse treatment. Certain profiles stood out. Females appeared in treatment more often (51.8 percent of their spells) than males (38.2 percent), with opiate treatment prevalent among 75.7 percent of treated women versus 60.1 percent of men. Age groups 35 to 49 showed the highest treatment rates, peaking at 52.1 percent for those 40 to 49.[1]

Offense types influenced access too. Theft convictions carried the highest treatment match at 61 percent, largely driven by opiate cases. Shorter stays correlated with treatment: spells of eight to 14 days doubled the linkage rate of seven days or fewer (41 percent versus 19.6 percent). These insights highlight systemic factors shaping who receives care inside.[1]

OST Delivers Clear Mortality Benefits

OST, which includes methadone or buprenorphine to maintain tolerance and curb illicit opioid use, proved transformative for opiate-dependent leavers. Among 61,322 relevant spells, 46,214 ended with OST administration. Those individuals recorded a 0.16 percent all-cause mortality rate (75 deaths), compared to 0.35 percent (53 deaths) without it – a raw halving of risk.[1]

Adjusting for factors like age, sex, and offense via a Fine-Gray competing risks model confirmed the edge: a sub-distribution hazard ratio of 0.50 for all-cause death (95 percent confidence interval 0.35-0.72), signaling a 50 percent reduction. Drug-related mortality followed suit, dropping from 0.26 percent to 0.12 percent, with an adjusted hazard ratio of 0.46 (95 percent CI 0.30-0.70) – a 54 percent cut.[1]

Methadone dominated OST use at 83 percent (mostly maintenance dosing), with buprenorphine rarer. The analysis excluded newer long-acting injectables like Buvidal due to limited uptake during the study window. Yet these findings echo prior work, such as a 2017 English study showing 75 percent lower all-cause and 85 percent lower drug-poisoning mortality post-release.[3]

Peak danger hit within the first 10 days across groups, but opiate-treated leavers bore the brunt over four weeks. Drug causes claimed 72.9 percent of their deaths, reinforcing OST’s role in bridging to community care.[1]

Reincarceration Trade-Off and Policy Horizons

OST offered no panacea. It correlated with a 16 percent higher reincarceration risk (sub-distribution hazard ratio 1.16, 95 percent CI 1.11-1.21), reaching 19 percent for opiate and alcohol cases combined. Opiate leavers topped return rates at 19.78 percent, possibly tied to ongoing needs unmet outside.[1]

• 39.6 percent of spells matched treatment overall.
• 62.1 percent of four-week deaths drug-related.
• OST halved all-cause mortality risk (SHR 0.50).
• OST cut drug deaths by 54 percent (SHR 0.46).
• Females: 51.8 percent treatment rate; theft offenses: 61 percent.

Still, the mortality gains dominate. With Buvidal now in every English prison – albeit sparingly – these results bolster calls for expansion. Sustained treatment could avert more tragedies, even as systems grapple with recidivism. The report urges deeper probes into opiate users and seamless community handoffs to maximize survival odds beyond those first perilous weeks.[1][2]

Read the full report for detailed charts and models.[1]